PL2744895T3 - Usuwanie zanieczyszczających wirusów z preparatów aav - Google Patents
Usuwanie zanieczyszczających wirusów z preparatów aavInfo
- Publication number
- PL2744895T3 PL2744895T3 PL12758663T PL12758663T PL2744895T3 PL 2744895 T3 PL2744895 T3 PL 2744895T3 PL 12758663 T PL12758663 T PL 12758663T PL 12758663 T PL12758663 T PL 12758663T PL 2744895 T3 PL2744895 T3 PL 2744895T3
- Authority
- PL
- Poland
- Prior art keywords
- removal
- contaminating viruses
- aav preparations
- aav
- preparations
- Prior art date
Links
- 241000700605 Viruses Species 0.000 title 1
- 238000002360 preparation method Methods 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D61/00—Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
- B01D61/14—Ultrafiltration; Microfiltration
- B01D61/145—Ultrafiltration
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D61/00—Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
- B01D61/14—Ultrafiltration; Microfiltration
- B01D61/16—Feed pretreatment
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D71/00—Semi-permeable membranes for separation processes or apparatus characterised by the material; Manufacturing processes specially adapted therefor
- B01D71/06—Organic material
- B01D71/08—Polysaccharides
- B01D71/10—Cellulose; Modified cellulose
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C12N7/02—Recovery or purification
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D2311/00—Details relating to membrane separation process operations and control
- B01D2311/04—Specific process operations in the feed stream; Feed pretreatment
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D2311/00—Details relating to membrane separation process operations and control
- B01D2311/26—Further operations combined with membrane separation processes
- B01D2311/2623—Ion-Exchange
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D2311/00—Details relating to membrane separation process operations and control
- B01D2311/26—Further operations combined with membrane separation processes
- B01D2311/2649—Filtration
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/14011—Baculoviridae
- C12N2710/14041—Use of virus, viral particle or viral elements as a vector
- C12N2710/14043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vectore
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/14011—Baculoviridae
- C12N2710/14051—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14051—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14311—Parvovirus, e.g. minute virus of mice
- C12N2750/14332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14311—Parvovirus, e.g. minute virus of mice
- C12N2750/14351—Methods of production or purification of viral material
Landscapes
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Water Supply & Treatment (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Plant Pathology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Solid-Sorbent Or Filter-Aiding Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161532176P | 2011-09-08 | 2011-09-08 | |
| EP11180594 | 2011-09-08 | ||
| PCT/NL2012/050619 WO2013036118A1 (en) | 2011-09-08 | 2012-09-07 | Removal of contaminating viruses from aav preparations |
| EP12758663.4A EP2744895B1 (en) | 2011-09-08 | 2012-09-07 | Removal of contaminating viruses from aav preparations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2744895T3 true PL2744895T3 (pl) | 2016-04-29 |
Family
ID=47832422
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL12758663T PL2744895T3 (pl) | 2011-09-08 | 2012-09-07 | Usuwanie zanieczyszczających wirusów z preparatów aav |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US9840694B2 (cg-RX-API-DMAC7.html) |
| EP (3) | EP2990477B8 (cg-RX-API-DMAC7.html) |
| JP (2) | JP6198278B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR101961347B1 (cg-RX-API-DMAC7.html) |
| CN (2) | CN107502597A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2012304993B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112014005255A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2847604A1 (cg-RX-API-DMAC7.html) |
| DK (1) | DK2744895T3 (cg-RX-API-DMAC7.html) |
| EA (1) | EA027511B1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2558168T3 (cg-RX-API-DMAC7.html) |
| HU (1) | HUE026579T2 (cg-RX-API-DMAC7.html) |
| IL (1) | IL231398A (cg-RX-API-DMAC7.html) |
| MX (1) | MX349601B (cg-RX-API-DMAC7.html) |
| PL (1) | PL2744895T3 (cg-RX-API-DMAC7.html) |
| PT (1) | PT2744895E (cg-RX-API-DMAC7.html) |
| SI (1) | SI2744895T1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2013036118A1 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA201401714B (cg-RX-API-DMAC7.html) |
Families Citing this family (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2990477B8 (en) * | 2011-09-08 | 2018-10-31 | uniQure IP B.V. | Removal of contaminating viruses from aav preparations |
| CA2927366A1 (en) | 2013-10-24 | 2015-04-30 | Uniqure Ip B.V. | Aav-5 pseudotyped vector for gene therapy for neurological diseases |
| WO2015191508A1 (en) | 2014-06-09 | 2015-12-17 | Voyager Therapeutics, Inc. | Chimeric capsids |
| SG11201703148TA (en) | 2014-11-05 | 2017-05-30 | Voyager Therapeutics Inc | Aadc polynucleotides for the treatment of parkinson's disease |
| CA3193811A1 (en) | 2014-11-14 | 2016-05-19 | Voyager Therapeutics, Inc. | Compositions and methods of treating amyotrophic lateral sclerosis (als) |
| DK3218386T3 (da) | 2014-11-14 | 2021-06-07 | Voyager Therapeutics Inc | Modulatorisk polynukleotid |
| HK1244849B (en) * | 2014-11-28 | 2020-04-09 | Uniqure Ip B.V. | Dna impurities in a composition comprising a parvoviral virion |
| US11697825B2 (en) | 2014-12-12 | 2023-07-11 | Voyager Therapeutics, Inc. | Compositions and methods for the production of scAAV |
| US10174321B2 (en) | 2014-12-24 | 2019-01-08 | Uniqure Ip B.V. | RNAI induced huntingtin gene suppression |
| EP3054007A1 (en) | 2015-02-09 | 2016-08-10 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Recombinant adeno-associated virus particle purification comprising an immuno-affinity purification step |
| WO2017189964A2 (en) | 2016-04-29 | 2017-11-02 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
| EP3448874A4 (en) | 2016-04-29 | 2020-04-22 | Voyager Therapeutics, Inc. | COMPOSITIONS FOR TREATING A DISEASE |
| US11951121B2 (en) | 2016-05-18 | 2024-04-09 | Voyager Therapeutics, Inc. | Compositions and methods for treating Huntington's disease |
| AU2017267665C1 (en) | 2016-05-18 | 2023-10-05 | Voyager Therapeutics, Inc. | Modulatory polynucleotides |
| CN110650673B (zh) | 2016-08-30 | 2024-04-09 | 加利福尼亚大学董事会 | 用于生物医学靶向和递送的方法以及用于实践该方法的装置和系统 |
| EP3618839A4 (en) | 2017-05-05 | 2021-06-09 | Voyager Therapeutics, Inc. | Compositions and methods of treating amyotrophic lateral sclerosis (als) |
| CN119491003A (zh) | 2017-05-05 | 2025-02-21 | 沃雅戈治疗公司 | 治疗亨廷顿病的组合物和方法 |
| JOP20190269A1 (ar) | 2017-06-15 | 2019-11-20 | Voyager Therapeutics Inc | بولي نوكليوتيدات aadc لعلاج مرض باركنسون |
| WO2019018342A1 (en) | 2017-07-17 | 2019-01-24 | Voyager Therapeutics, Inc. | NETWORK EQUIPMENT TRACK GUIDE SYSTEM |
| US20200263199A1 (en) | 2017-09-29 | 2020-08-20 | Voyager Therapeutics, Inc. | Rescue of central and peripheral neurological phenotype of friedreich's ataxia by intravenous delivery |
| WO2019079242A1 (en) | 2017-10-16 | 2019-04-25 | Voyager Therapeutics, Inc. | TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS) |
| AU2018352236B2 (en) | 2017-10-16 | 2025-04-10 | The Curators Of The University Of Missouri | Treatment of amyotrophic lateral sclerosis (ALS) |
| DK3740222T5 (da) | 2018-01-17 | 2024-08-26 | Meiragtx Uk Ltd | Modificeret RAAV-capsidprotein til genterapi |
| US12319929B2 (en) | 2018-05-15 | 2025-06-03 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of Parkinson's disease |
| EP3850098A1 (en) | 2018-09-12 | 2021-07-21 | uniQure IP B.V. | Rnai induced c9orf72 suppression for the treatment of als/ftd |
| CA3114621A1 (en) | 2018-09-28 | 2020-04-02 | Voyager Therapeutics, Inc. | Frataxin expression constructs having engineered promoters and methods of use thereof |
| CA3115524A1 (en) * | 2018-10-15 | 2020-04-23 | Win Den Cheung | Methods for measuring the infectivity of replication defective viral vectors and viruses |
| WO2020104480A1 (en) | 2018-11-19 | 2020-05-28 | Uniqure Biopharma B.V. | Adeno-associated virus vectors for expressing fviii mimetics and uses thereof |
| EP3884067A1 (en) | 2018-11-19 | 2021-09-29 | uniQure IP B.V. | A companion diagnostic to monitor the effects of gene therapy |
| WO2020104469A1 (en) | 2018-11-19 | 2020-05-28 | Uniqure Ip B.V. | Method and means to deliver mirna to target cells |
| WO2020104295A1 (en) | 2018-11-19 | 2020-05-28 | Uniqure Ip B.V. | Rnai induced reduction of ataxin-3 for the treatment of spinocerebellar ataxia type 3 |
| WO2020150556A1 (en) * | 2019-01-18 | 2020-07-23 | Voyager Therapeutics, Inc. | Methods and systems for producing aav particles |
| KR20210126096A (ko) | 2019-02-15 | 2021-10-19 | 상가모 테라퓨틱스, 인코포레이티드 | 재조합 aav를 제조하기 위한 조성물 및 방법 |
| WO2020219897A1 (en) * | 2019-04-24 | 2020-10-29 | Biogen Ma Inc. | Methods for production of recombinant adeno-associated viruses |
| EP3999119B1 (en) | 2019-07-15 | 2024-09-11 | Meiragtx UK II Limited | Modified aav capsid proteins for treatment of arthritic disease |
| WO2021053018A1 (en) | 2019-09-16 | 2021-03-25 | Uniqure Ip B.V. | Targeting misspliced transcripts in genetic disorders |
| AU2020398178A1 (en) | 2019-12-04 | 2022-06-09 | Sangamo Therapeutics, Inc. | Novel compositions and methods for producing recombinant AAV |
| WO2021119404A1 (en) * | 2019-12-12 | 2021-06-17 | Emd Millipore Corporation | Intensified virus filtration using diafiltration buffer |
| EP4097239A2 (en) * | 2020-01-29 | 2022-12-07 | Voyager Therapeutics, Inc. | Methods and systems for producing aav particles |
| EP4112735A4 (en) * | 2020-02-28 | 2023-09-06 | Asahi Kasei Medical Co., Ltd. | Method for evaluating viral clearance performance |
| WO2021204872A1 (en) | 2020-04-07 | 2021-10-14 | Uniqure Ip B.V. | Gene constructs for silencing angiopoietin-like 3 (angptl3) and uses thereof |
| CN115427561B (zh) | 2021-03-09 | 2024-06-04 | 辉大(上海)生物科技有限公司 | 工程化CRISPR/Cas13系统及其用途 |
| WO2022208201A1 (en) * | 2021-03-30 | 2022-10-06 | 3M Innovative Properties Company | Hollow-fiber membrane comprising polysulfone and polyoxazoline and method making thereof |
| WO2022214635A1 (en) | 2021-04-08 | 2022-10-13 | Stichting Vu | Nucleic acid molecules for compensation of stxbp1 haploinsufficiency and their use in the treatment of stxbp1-related disorders |
| AU2022285138A1 (en) | 2021-06-02 | 2023-11-30 | Uniqure Biopharma B.V. | Adeno-associated virus vectors modified to bind high-density lipoprotein |
| JP2024523445A (ja) | 2021-06-21 | 2024-06-28 | ユニキュアー バイオファーマ ビー．ブイ． | α－シヌクレインをサイレンシングするための遺伝子構築物及びその使用 |
| WO2022268811A1 (en) | 2021-06-21 | 2022-12-29 | Uniqure Biopharma B.V. | Improved lysis procedures |
| WO2023283962A1 (en) | 2021-07-16 | 2023-01-19 | Huigene Therapeutics Co., Ltd. | Modified aav capsid for gene therapy and methods thereof |
| JP2025512061A (ja) | 2022-04-12 | 2025-04-16 | ユニキュアー バイオファーマ ビー．ブイ． | Ｓｎｃａの核酸調節 |
| WO2023198745A1 (en) | 2022-04-12 | 2023-10-19 | Uniqure Biopharma B.V. | Nucleic acid regulation of apoe |
| US20250230437A1 (en) | 2022-04-12 | 2025-07-17 | Uniqure Biopharma B.V. | Novel systems for nucleic acid regulation |
| WO2023198702A1 (en) | 2022-04-12 | 2023-10-19 | Uniqure Biopharma B.V. | Nucleic acid regulation of c9orf72 |
| US20240209324A1 (en) * | 2022-12-22 | 2024-06-27 | Cytiva Us Llc | Virus separation |
| AU2024256392A1 (en) | 2023-04-18 | 2025-10-23 | Uniqure Biopharma B.V. | Gene delivery vehicles comprising rna and antibodies |
| AU2024258047A1 (en) | 2023-04-18 | 2025-10-23 | Uniqure Biopharma B.V. | Novel neurotropic adeno-associated virus capsids with detargeting of peripheral organs |
| WO2024261220A1 (en) | 2023-06-23 | 2024-12-26 | Uniqure Biopharma B.V. | Novel fragile x constructs |
| WO2025051805A1 (en) | 2023-09-04 | 2025-03-13 | Uniqure Biopharma B.V. | Novel neurotropic recombinant adeno-associated virus particles |
| WO2025078606A1 (en) | 2023-10-11 | 2025-04-17 | Uniqure Biopharma B.V. | Further novel systems for nucleic acid regulation |
| WO2025078598A1 (en) | 2023-10-11 | 2025-04-17 | Uniqure Biopharma B.V. | Novel nucleic acid regulation of huntingtin gene |
| WO2025078602A1 (en) | 2023-10-11 | 2025-04-17 | Uniqure Biopharma B.V. | Nucleic acid regulation of msh3 in repeat expansion disorders |
| WO2025114524A1 (en) | 2023-11-30 | 2025-06-05 | Uniqure Biopharma B.V. | Formulations for viral drug products |
| WO2025219443A1 (en) | 2024-04-19 | 2025-10-23 | Uniqure Biopharma B.V. | Nucleic acid for a1at regulation |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4745051A (en) | 1983-05-27 | 1988-05-17 | The Texas A&M University System | Method for producing a recombinant baculovirus expression vector |
| AU4270196A (en) | 1994-10-07 | 1996-05-02 | Lutz Gissmann | Papilloma virus-like particles, fusion proteins and process for producing the same |
| DE19709186C2 (de) | 1997-03-06 | 1999-10-14 | Medigene Ag | Filtrationsverfahren zur Trennung von Viren |
| US6103526A (en) | 1998-10-08 | 2000-08-15 | Protein Sciences Corporation | Spodoptera frugiperda single cell suspension cell line in serum-free media, methods of producing and using |
| JP2002538770A (ja) | 1998-11-10 | 2002-11-19 | ユニバーシティ オブ ノース カロライナ アット チャペル ヒル | ウイルスベクターとその製造及び投与の方法 |
| US6593123B1 (en) * | 2000-08-07 | 2003-07-15 | Avigen, Inc. | Large-scale recombinant adeno-associated virus (rAAV) production and purification |
| US6723551B2 (en) | 2001-11-09 | 2004-04-20 | The United States Of America As Represented By The Department Of Health And Human Services | Production of adeno-associated virus in insect cells |
| AU2003212708A1 (en) | 2002-03-05 | 2003-09-16 | Stichting Voor De Technische Wetenschappen | Baculovirus expression system |
| US20050009168A1 (en) * | 2003-05-12 | 2005-01-13 | Robbins Joan Marie | Methods and apparatus for Adeno associated virus purification |
| RU2457252C2 (ru) * | 2006-06-21 | 2012-07-27 | Амстердам Молекьюла Терапьютикс (Амт) Ип Б.В. | AAV ВЕКТОРЫ С УСОВЕРШЕНСТВОВАННЫМИ Rep-КОДИРУЮЩИМИ ПОСЛЕДОВАТЕЛЬНОСТЯМИ, ИСПОЛЬЗУЕМЫМИ В СИСТЕМАХ ПРОДУКЦИИ НА ОСНОВЕ КЛЕТОК НАСЕКОМЫХ |
| US20080299545A1 (en) * | 2007-03-06 | 2008-12-04 | Shuyuan Zhang | Chromatographic methods for assessing adenovirus purity |
| US20100323429A1 (en) * | 2008-04-10 | 2010-12-23 | Yu-Chen Hu | Methods for purifying baculovirus |
| ES2881050T3 (es) * | 2009-06-16 | 2021-11-26 | Genzyme Corp | Métodos mejorados para la purificación de vectores de AAV recombinantes |
| ES2680915T3 (es) * | 2010-01-28 | 2018-09-11 | The Children's Hospital Of Philadelphia | Plataforma de fabricación escalable para la purificación de vectores virales y vectores virales purificados de este modo para su utilización en terapia génica |
| EP2990477B8 (en) * | 2011-09-08 | 2018-10-31 | uniQure IP B.V. | Removal of contaminating viruses from aav preparations |
-
2012
- 2012-09-07 EP EP15186937.7A patent/EP2990477B8/en not_active Revoked
- 2012-09-07 EP EP12758663.4A patent/EP2744895B1/en active Active
- 2012-09-07 WO PCT/NL2012/050619 patent/WO2013036118A1/en not_active Ceased
- 2012-09-07 US US14/343,884 patent/US9840694B2/en active Active
- 2012-09-07 HU HUE12758663A patent/HUE026579T2/en unknown
- 2012-09-07 PL PL12758663T patent/PL2744895T3/pl unknown
- 2012-09-07 CN CN201710697343.1A patent/CN107502597A/zh active Pending
- 2012-09-07 PT PT127586634T patent/PT2744895E/pt unknown
- 2012-09-07 SI SI201230372T patent/SI2744895T1/sl unknown
- 2012-09-07 AU AU2012304993A patent/AU2012304993B2/en not_active Ceased
- 2012-09-07 EA EA201490583A patent/EA027511B1/ru not_active IP Right Cessation
- 2012-09-07 CN CN201280049899.5A patent/CN103857790B/zh not_active Expired - Fee Related
- 2012-09-07 DK DK12758663.4T patent/DK2744895T3/en active
- 2012-09-07 BR BR112014005255A patent/BR112014005255A2/pt active Search and Examination
- 2012-09-07 ES ES12758663.4T patent/ES2558168T3/es active Active
- 2012-09-07 CA CA2847604A patent/CA2847604A1/en not_active Abandoned
- 2012-09-07 KR KR1020147009146A patent/KR101961347B1/ko not_active Expired - Fee Related
- 2012-09-07 MX MX2014002733A patent/MX349601B/es active IP Right Grant
- 2012-09-07 JP JP2014529633A patent/JP6198278B2/ja not_active Expired - Fee Related
- 2012-09-07 EP EP18191023.3A patent/EP3425044A1/en not_active Withdrawn
-
2014
- 2014-03-06 IL IL231398A patent/IL231398A/en active IP Right Grant
- 2014-03-07 ZA ZA2014/01714A patent/ZA201401714B/en unknown
-
2017
- 2017-06-27 JP JP2017125458A patent/JP6624690B2/ja not_active Expired - Fee Related
- 2017-12-08 US US15/836,220 patent/US10253301B2/en not_active Expired - Fee Related
-
2019
- 2019-03-20 US US16/359,593 patent/US20190218523A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201401714B (en) | Removal of contaminating viruses from aav preparations | |
| ZA201501018B (en) | Compounds for the treatment of paramoxyvirus viral infections | |
| IL221158B (en) | Methods for vector purification of the aav virus | |
| SG11201404014PA (en) | Methods for increasing the infectivity of viruses | |
| ZA201405820B (en) | Piperidino-pyrimidine derivatives for the treatment of viral infections | |
| SG11201404361UA (en) | Methods for increasing the infectivity of viruses | |
| SG10201610753YA (en) | Purification of virus like particles | |
| PT2620391E (pt) | Método para retirar de armazenamento embalagens de medicamentos | |
| IL237362A0 (en) | A method of securing operating systems against malware attacks | |
| EP2786300A4 (en) | PROTECTION OF ENTRIES AGAINST MALWARE SOFTWARE | |
| IL230487A0 (en) | Benzofuran compounds for the treatment of hepatitis c virus infections | |
| AP2014007650A0 (en) | Inhibition of viral gene expression | |
| ZA201306561B (en) | Removing compounds from wine | |
| IL230702A0 (en) | A test to detect the DNA of the jc virus | |
| ZA201308011B (en) | Processes for preparing inhibitors of the hepatitis c virus | |
| EP2701735A4 (en) | LIQUID VACCINE COMPOSITIONS | |
| IL231876A0 (en) | A system for the purification of viral vectors | |
| ZA201306342B (en) | The treatment of viral infections | |
| PL2793956T3 (pl) | Sposób usuwania wirusa z roztworu białka | |
| HUE036284T2 (hu) | Eljárás szilícium-karbid elõállítására | |
| PT2702045T (pt) | Método inovador para a preparação de etravirina | |
| EP2656905B8 (de) | Entquickung von Lösungen durch Ultrafiltration | |
| GB201211930D0 (en) | Concept for all killer viruses | |
| GB201217331D0 (en) | Novel compound useful for the treatment of infectious diseases | |
| PL394819A1 (pl) | Sposób wytwarzania krysztalów tlenkowych |